Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NSI-566 in chronic ischemic stroke
NCT03296618Phase 1Unknown
- Sponsor
- Suzhou Neuralstem Biopharmaceutical
- Start
- Jun 2012
- Primary completion
- May 2018
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NSI-566 in ischemic stroke, sponsored by Suzhou Neuralstem Biopharmaceutical. Primary endpoint: Adverse Events at 24 months. Status: unknown.
02
Drugs
NSI-566
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT03296618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03296618.